THERAVANCE COMPLETES ENROLLMENT FOR ANTIBIOTIC TRIAL
Theravance has completed enrollment in its first Phase III clinical program with the investigational antibiotic telavancin in patients with complicated skin and skin structure infections due to Gram-positive bacteria. The trial will include patients with resistant strains of disease including methicillin-resistant Staphylococcus aureus (MRSA).
Telavancin inhibits the formation of the bacterial cell wall and disrupts bacterial cell membrane integrity. The company said in a statement that it believes the additive mechanisms of action seen with telavancin speed bacterial killing while also reducing the risks of inducing resistance to telavancin or cross-resistance with other antibiotics.